An interventional study of Self-sampled HPV DNA testing and Clinician-sampled HPV DNA test in Uterine Cervical Neoplasms, sponsored by National Healthcare Group Polyclinics. Recruiting at 1 site in Singapore. Open to female participants aged 30 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by National Healthcare Group Polyclinics · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Uterine Cervical Neoplasms with a site in Singapore — 2 open to participants now, 7 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Singapore.
Among the 18 studies in Uterine Cervical Neoplasms with a site in Singapore, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 with no phase, and was the 17th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →2 of the 18 studies in Uterine Cervical Neoplasms with a site in Singapore are open now. Recruiting first, the newest first:
National University Hospital, Singapore · Sites in Singapore
Ages 21+ · Women only
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 30 Years to 69 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 8
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 289 across the 15 interventional studies, 308 across the 2 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
National Healthcare Group Polyclinics is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
National Healthcare Group Polyclinics has 1 study filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Uterine Cervical Neoplasms with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06528184National Healthcare Group PolyclinicsEvaluating the Impact of Different Methods of HPV DNA Testing for Cervical Cancer Screening in Primary Care Settings | 2026-12 |
| NCT05081609Ascendis Pharma Oncology Division A/SA Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | 2027-08 |
| NCT06023862Yonsei UniversityA Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Uterine Cervical Neoplasms with a site in Singapore, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective of the study is to determine the extent that offering of self-sampling in addition to clinician-sampling Human Papillomavirus (HPV) DNA testing will increase detection of HPV DNA through an increase in uptake rates of cervical cancer screening as compared to offering clinician-sampling HPV DNA testing alone.
The hypothesis is that offering additional self-sampling will increase the detection of high-risk HPV DNA by at least 7.7%.
This study is a pragmatic, multi-center, 1:1 randomized controlled trial designed to evaluate the impact of self-sampling HPV DNA testing on clinical outcomes and cost-effectiveness in cervical cancer screening. The trial will compare 2 approaches to HPV DNA testing within public primary care settings.
Participants in the intervention arm will first be offered a clinician-sampling HPV DNA test. If they decline, they will be offered the option of self-sampling HPV DNA test. The control arm will follow the standard protocol of offering only the conventional clinician-sampling HPV DNA test, reflecting the current standard of care in cervical cancer screening.
This study seeks to provide robust evidence on whether self-sampling can improve clinical outcomes, be cost-effective and be feasibility implemented in routine public primary healthcare settings. The findings are expected to inform future guidelines and policies for cervical cancer screening programs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will only be offered clinician-sampling for HPV DNA testing to determine if they are agreeable to undergo screening.
Diagnostic Test: Clinician-sampled HPV DNA test
Participants will be offered clinician-sampling or self-sampling for HPV DNA testing to determine if they are agreeable to undergo screening using either modality.
Diagnostic Test: Self-sampled HPV DNA testing · Diagnostic Test: Clinician-sampled HPV DNA test
Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)
Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
Detection of high-risk Human Papillomavirus (HPV) DNA
Difference in detection of high-risk HPV DNA between 2 arms
Time frame: 3 months
Uptake of cervical cancer screening
Difference in uptake of cervical cancer screening between 2 arms. Based on the number of cervical cancer screening tests that are processed and have available results.
Time frame: 3 months
Colposcopy referrals
Difference in colposcopy referrals between 2 arms. Based on the number of colposcopy referrals made to the tertiary hospital for abnormal cervical cancer screening test results in either arm.
Time frame: 2 years
Detection of cervical intraepithelial neoplasia (CIN) 2, CIN 3 and cervical cancers
Difference in detection of CIN 2, CIN 3 and cervical cancers between both arms.
Time frame: 2 years
Treatments for CIN 2, CIN 3 and cervical cancers
Difference in treated CIN 2, CIN 3 and cervical cancers between both arms. Based on the number of participants with CIN 2, CIN 3 and cervical cancers that have undergone treatments by a gynecologist in either arm.
Time frame: 2 years
Cost-effectiveness of cervical cancer screening
Difference in cost-effectiveness of offering cervical cancer screening between both arms. This includes the cost of screening and follow-up visits in primary care, the cost of further investigations in primary and tertiary care and the cost of treatment for CIN and cervical cancer in tertiary care.
Time frame: 2 years
Facilitators and barriers of uptake of cervical cancer screening
Assessing the factors associated with uptake of cervical cancer screening. These factors include demographics of participants (age, ethnicity, education level, marital status, housing type, employment status), Body Mass Index, obstetrics-related factors (menopausal status, pregnancies, previous cervical cancer screening tests, use of tampons or menstrual cups, previous HPV vaccinations) as well as beliefs and attitudes towards cervical cancer screening. These variables will be collected from questionnaires.
Time frame: 1 year
Feasibility of self-sampling cervical cancer screening
Assessing the preferences for next screening and the experience of the sampling procedure (ease of conducting, comfort, anxiety, embarrassment, unpleasantness and trusting of results) from questionnaires.
Time frame: 1 year
Risk factors for cervical cancer and CIN
Assessing the factors associated with cervical cancer and CIN. These factors include demographics of participants, family history of cervical cancer, smoking status, use of contraceptives, immunosuppressive conditions and sexual history and obstetrics-related factors. These variables will be collected from questionnaires.
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 28 months is below that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Healthcare Group Polyclinics